Utama › Limfoma Bukan Hodgkin
Kajian klinikal Limfoma Bukan Hodgkin sedang mengambil peserta di AS
127 kajian untuk Limfoma Bukan Hodgkin sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX31 kajian
- New York City, NY31 kajian
- Boston, MA26 kajian
- Nashville, TN21 kajian
- Philadelphia, PA20 kajian
- Baldwin Park, CA19 kajian
- Atlanta, GA18 kajian
- Chicago, IL18 kajian
- Columbus, OH18 kajian
- Milwaukee, WI18 kajian
- Washington, DC18 kajian
- Dallas, TX17 kajian
- Durham, NC16 kajian
- Seattle, WA16 kajian
- Portland, OR15 kajian
- Rochester, MN14 kajian
- Miami, FL14 kajian
- Omaha, NE14 kajian
- Denver, CO14 kajian
- Cleveland, OH13 kajian
- Salt Lake City, UT13 kajian
- Mountain View, CA12 kajian
- St. Louis, MO11 kajian
- Aurora, CO11 kajian
- Los Angeles, CA9 kajian
- Tampa, FL9 kajian
- Jacksonville, FL9 kajian
- Cincinnati, OH9 kajian
- San Francisco, CA9 kajian
- Pittsburgh, PA8 kajian
- San Diego, CA8 kajian
- Baltimore, MD8 kajian
- Ann Arbor, MI8 kajian
- Cedar Rapids, IA8 kajian
- Clifton, NJ7 kajian
- Buffalo, NY7 kajian
- Kansas City, MO7 kajian
- Edison, NJ7 kajian
- Birmingham, AL7 kajian
- Queens, NY7 kajian
Mengikut negeri
- Alabama7 kajian
- Arizona14 kajian
- Arkansas5 kajian
- California42 kajian
- Colorado20 kajian
- Connecticut8 kajian
- Delaware4 kajian
- Florida32 kajian
- Georgia21 kajian
- Hawaii3 kajian
- Idaho3 kajian
- Illinois20 kajian
- Indiana10 kajian
- Iowa10 kajian
- Kansas9 kajian
- Kentucky5 kajian
- Louisiana6 kajian
- Maine4 kajian
- Maryland21 kajian
- Massachusetts28 kajian
- Michigan13 kajian
- Minnesota19 kajian
- Mississippi3 kajian
- Missouri10 kajian
- Montana3 kajian
- Nebraska15 kajian
- New Jersey13 kajian
- New Mexico4 kajian
- New York40 kajian
- North Carolina24 kajian
- North Dakota3 kajian
- Ohio34 kajian
- Oklahoma3 kajian
- Oregon15 kajian
- Pennsylvania26 kajian
- Rhode Island5 kajian
- South Carolina5 kajian
- South Dakota3 kajian
- Tennessee24 kajian
- Texas48 kajian
- Utah14 kajian
- Virginia13 kajian
- Washington20 kajian
- West Virginia3 kajian
- Wilayah Columbia4 kajian
- Wisconsin20 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Mengambil pesertaFasa 1
Umur 12 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Mengambil pesertaFasa 1
Umur 12 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT02917083Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07763210A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07582432T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 3 hingga 39 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05645107NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07052305A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Mengambil pesertaFasa 1/2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03223610A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07519772Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Mengambil pesertaFasa 2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05907759Epco, Zanu, Ritux for R/R FL or MZL
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04002947Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Mengambil pesertaFasa 1
Umur 18 hingga 100 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT05798897Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.